Article: Sorrento Therapeutics Analyst Says Coronavirus Antibody Cocktail One Of Few Non-Vaccine Options

Article - Media

Sorrento Therapeutics Analyst Says Coronavirus Antibody Cocktail One Of Few Non-Vaccine Options

Sorrento Therapeutics Inc (NASDAQ: SRNE) shares spiked 158% Friday after the company disclosed that it has identified an antibody that demonstrated 100% inhibition of SARS-CoV-2 virus infection.

The Sorrento Analyst

H.C. Wainwright analyst Raghuram Selvaraju has a Buy rating on Sorrento with a $24 price target.

Comment: Every placement  these guys do seems to sour.  Time for an investigation?

Competing Comment: Every placement is subject to naked short selling pressure, without an investigation you cannot know for sure.  Some companies do have histories. HCWainwreight appears to be one of them.